H3.3K27M SPECIFIC PEPTIDE VACCINE COMBINED WITH POLY-ICLC FOR THE TREATMENT OF NEWLY DIAGNOSED HLA-A2+H3.3K27M POSITIVE DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AS WELL AS OTHER NEWLY DIAGNOSED HLA-A2+H3.3K27M POSITIVE GLIOMAS

Registry ID

PNOC 007

Source registry

HEALTH_CANADA

Status

Pending

Study type

INTERVENTIONAL

Sponsor

PACIFIC PEDIATRIC NEURO-ONCOLOGY CONSORTIUM

Last update

2019-10-24

Conditions

• DIFFUSE INTRINSIC PONTINE GLIOMAS

Related clinical trials

• A PILOT STUDY OF SAFETY, TOLERABILITY, AND IMMUNOLOGICAL EFFECTS OF SURVAXM IN PEDIATRIC PATIENTS WITH PROGRESSIVE OR RELAPSED MEDULLOBLASTOMA, HIGH GRADE GLIOMA, EPENDYMOMA AND NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA

View on source registry